Usefulness of TNFR1 as biomarker of intracranial aneurysm in patients with spontaneous subarachnoid hemorrhage.

TNFR1 aneurysm biomarker spontaneous subarachnoid hemorrhage stroke

Journal

Future science OA
ISSN: 2056-5623
Titre abrégé: Future Sci OA
Pays: England
ID NLM: 101665030

Informations de publication

Date de publication:
05 Nov 2019
Historique:
entrez: 10 1 2020
pubmed: 10 1 2020
medline: 10 1 2020
Statut: epublish

Résumé

To determine the utility of TNF-α receptor (TNFR1) as a biomarker for the presence of aneurysms in patients with acute subarachnoid hemorrhage (SAH). This is a prospective study in patients with acute spontaneous SAH. Arterial blood from catheter near aneurysm and peripheral venous blood samples are collected. TNFR1 levels were analyzed in patients with and without aneurysm. 80 patients were included, 58 were analyzed. 41 patients (70.7%) had an aneurysm. Venous TNFR1 levels >1658 pg/ml had 46.3% sensitivity and 94.1% specificity for aneurysms presence. TNFR1 >1658 pg/ml was also an independent predictor for its presence (odds ratio = 12.03 [1.13-128.16]; p = 0.039). High levels of TNFR1 in peripheral venous blood are associated with the presence of aneurysm in patients with acute SAH.

Identifiants

pubmed: 31915532
doi: 10.2144/fsoa-2019-0090
pmc: PMC6920737
doi:

Types de publication

Journal Article

Langues

eng

Pagination

FSO431

Informations de copyright

© 2019 Joan Montaner.

Déclaration de conflit d'intérêts

Financial & competing interests disclosure This project was partially funded by the followings projects from ‘Instituto de Salud Carlos III’: INVICTUS+ (RD16/0019/0015); F Mancha is supported by Río Hortega research contract (CM16/00015) and A Bustamante is supported by a Juan Rodés research contract (JR16/00008). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Références

J Psychiatr Res. 2014 Jun;53:166-72
pubmed: 24576746
Acta Neuropathol Commun. 2014 Mar 31;2:34
pubmed: 24685329
Semin Neurol. 2010 Nov;30(5):537-44
pubmed: 21207346
Gac Med Mex. 2014 Jul-Aug;150(4):334-44
pubmed: 25098219
Neuroscience. 2015 Aug 27;302:2-22
pubmed: 26117714
Neurol Med Chir (Tokyo). 2015;55(3):214-29
pubmed: 25761423
Curr Drug Saf. 2012 Jul;7(3):190-6
pubmed: 22950379
Stroke. 2008 Mar;39(3):1049-55
pubmed: 18258833
Dis Mon. 2011 Oct;57(10):647-55
pubmed: 22036120
J Am Coll Surg. 1994 Feb;178(2):132-8
pubmed: 8173722
Neurocrit Care. 2019 Aug;31(1):107-115
pubmed: 30673997
Clin Psychopharmacol Neurosci. 2017 Aug 31;15(3):269-275
pubmed: 28783937
Eur J Radiol. 2013 Oct;82(10):1598-605
pubmed: 23399038
Biomarkers. 2014 Mar;19(2):95-108
pubmed: 24499240

Auteurs

Reyes de Torres (R)

Neurology Unit, Hospital Virgen Macarena, Seville, Spain.

Fernando Mancha (F)

Neurovascular Laboratory, Instituto de Biomedicina de Sevilla, Seville, Spain.

Alejandro Bustamante (A)

Neurovascular Research Laboratory, Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.

Patricia Canhao (P)

Neuroradiology Department, Centro Hospitalar Lisboa Central, Lisboa, Portugal.

Isabel Fragata (I)

Neuroradiology Department, Centro Hospitalar Lisboa Norte, Lisboa, Portugal.
Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, Lisboa, Portugal.

Joan Montaner (J)

Neurology Unit, Hospital Virgen Macarena, Seville, Spain.
Neurovascular Research Laboratory, Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.

Classifications MeSH